The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Open accessAbstract
PURPOSE: Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements, as opposed to unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used in solid tumors. We aimed to compare response assessment by bidimensional versus unidimensional irRC in patients with advanced melanoma treated with ipilimumab. EXPERIMENTAL DESIGN: Fifty-seven patients with advanced melanoma treated with ipilimumab in a phase II, expanded access trial were studied. Bidimensional tumor measurement records prospectively conducted during the trial were reviewed to generate a second set of measurements using unidimensional, longest diameter measurements. The percent changes of measurements at follow-up, best overall response, and time-to-progression (TTP) were compared between bidimensional and unidimensional irRC. Interobserver variability for bidimensional and unidimensional measurements was assessed in 25 randomly selected patients. RESULTS: The percent changes at follow-up scans were highly concordant between the 2 criteria (Spearman r: 0.953-0.965, first to fourth follow-up). The best immune-related response was highly concordant between the 2 criteria (κw = 0.881). TTP was similar between the bidimensional and unidimensional assessments (progression-free at 6 months: 70% vs. 81%, respectively). The unidimensional measurements were more reproducible than bidimensional measurements, with the 95% limits of agreement of (-16.1%, 5.8%) versus (-31.3%, 19.7%), respectively. CONCLUSION: irRC using the unidimensional measurements provided highly concordant response assessment compared with the bidimensional irRC, with less measurement variability. The use of unidimensional irRC is proposed to assess response to immunotherapy in solid tumors, given its simplicity, higher reproducibility, and high concordance with the bidimensional irRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More recently, immune-related response criteria (irRC) have been proposed and validated in malignant melanoma to better assess the variety of responses that can be generated upon imAbs [176,177].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationA concordance correlation coefficient to evaluate reproducibility.
Lin, L. I.-K. (1989) · Biometrics · doi:10.2307/2532051 · Cited by 8,785
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Cited by
Sorted by citations
Items 301–400 of 520
Considerations when treating high-grade pediatric glioma patients with immunotherapy
Crotty, E. E., Downey, K., Ferrerosa, L., Flores, C., Hegde, B., Raskin, S. I., Hwang, E. I., Vitanza, N. A., & Okada, H. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1855144 · Cited by 9
Samuelly, A., Stefano, R. F. D., Turco, F., Delcuratolo, M. D., Pisano, C., Saporita, I., Calabrese, M., Carfì, F. M., Tucci, M., & Buttigliero, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020307 · Cited by 8
Nie, R., Yuan, S., Wang, Y., Zou, X., Chen, S., Li, S., Duan, J., Zhou, J., Chen, G., Luo, T., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920929583 · Cited by 8
PACIFIC: Time for a surgical IIIA uprising
Pass, H. I. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.05.059 · Cited by 8
Ishihara, H., Takagi, T., Kondo, T., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., Ishida, H., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1261-5 · Cited by 8
Liu, Y., Yang, L., Zhang, F., Tang, B.-S., Zhao, L., Zhu, J.-R., Jin, Q., Wang, R., & Li, Y. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.07.006 · Cited by 8
Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events
Elsherif, S. B., Anderson, M. R., Chaudhry, A. A., Kumar, S. P., Gopireddy, D. R., Lall, C. G., & Bhosale, P. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.110062 · Cited by 8
Liu, W., Zhang, Y., Li, L., Zhu, Y., Ming, Z., Chen, W., Yang, R., Li, R., Chen, M., & Zhang, G. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103746 · Cited by 7
Meltzer, S., Negård, A., Bakke, K. M., Hamre, H. M., Kersten, C., Hofsli, E., Guren, M. G., Sørbye, H., Flatmark, K., & Ree, A. H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02004-0 · Cited by 8
Ma, Y., Jiang, X., Song, P., & Tang, W. (2024) · BioScience Trends · doi:10.5582/bst.2023.01436 · Cited by 10
Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines
DeBay, D. R., Brewer, K., LeBlanc, S. A., Weir, G. M., Stanford, M. M., Mansour, M., & Bowen, C. V. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.48 · Cited by 8
Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer
Zhang, L., Mai, W., Hao, B., Jiang, W., & Geng, Q. (2020) · Medicine · doi:10.1097/md.0000000000019790 · Cited by 8
Ferrara, R., Signorelli, D., Proto, C., Prelaj, A., Garassino, M. C., & Russo, G. L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-636 · Cited by 7
Immune-related response criteria: light and shadows
Merlano, M. C., Occelli, M., & Garrone, O. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000082 · Cited by 8
[Response criteria for malignant melanoma: RECIST and irRC].
Spiro, J., Maintz, D. C., & ten Persigehl, T. (2015) · PubMed · doi:10.1007/s00117-014-2763-y · Cited by 7
Liu, J.-Y., Xie, M., Shen, J., Yao, J., Lin, X.-W., Bao, X.-Y., Zhang, X., Liang, Y.-R., Yang, Y., Jiang, G.-G., et al. (2025) · Cancer Management and Research · doi:10.2147/cmar.s522136 · Cited by 7
Current Status of Immunotherapy for Non-Small-Cell Lung Cancer
Imbimbo, M., Russo, G. L., & Blackhall, F. H. (2016) · Tumori Journal · doi:10.5301/tj.5000537 · Cited by 7
Iyalomhe, O., & Farwell, M. D. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.010 · Cited by 7
Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Han, X., Sun, Q., Xu, M., Zhu, G., Gao, R., Ni, B., & Li, J. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1776127 · Cited by 7
Ruchalski, K. L., Anaokar, J. M., Benz, M., Dewan, R., Douek, M. L., & Goldin, J. G. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00802-8 · Cited by 7
Alberti, A., Lorini, L., Ravanelli, M., Perri, F., Vinches, M., Rondi, P., Romani, C., & Bossi, P. (2022) · Vaccines · doi:10.3390/vaccines10060885 · Cited by 7
Li, Y. F., Wang, Y., Zhou, J., Wei, Y., Lin, J., Yin, Y., Chen, G. M., Zhang, F. Y., Chen, S., Zhou, Z., et al. (2022) · World Journal of Oncology · doi:10.14740/wjon1481 · Cited by 7
Oriuchi, N., Endoh, H., & Kaira, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169394 · Cited by 8
Immunotherapy Assessment: A New Paradigm for Radiologists
Granata, V., Fusco, R., Setola, S. V., Simonetti, I., Picone, C., Simeone, E., Festino, L., Vanella, V., Vitale, M. G., Montanino, A., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020302 · Cited by 7
Mizuno, K., Imai, N., Yamamoto, T., Yokoyama, S., Yamamoto, K., Ito, T., Ishizu, Y., Honda, T., Kuzuya, T., Ishigami, M., et al. (2023) · Cancers · doi:10.3390/cancers15102853 · Cited by 7
Trial Design for Cancer Immunotherapy: A Methodological Toolkit
Saad, E., Coart, E., Deltuvaite-Thomas, V., Garcia-Barrado, L., Burzykowski, T., & Buyse, M. (2023) · Cancers · doi:10.3390/cancers15184669 · Cited by 8
Immunotherapy for Non-Small-Cell Lung Cancer: The Past 10 Years
Vansteenkiste, J., Craps, J., Brucker, N. D., & Wauters, I. (2015) · Future Oncology · doi:10.2217/fon.15.116 · Cited by 7
Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma
Bennani-Baiti, N., Thanarajasingam, G., & Ansell, S. A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1147350 · Cited by 7
Immunotherapy in Lung Cancer and the Role of Imaging
Carter, B. W. (2018) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2018.02.004 · Cited by 7
Post-immunotherapy imaging in lung cancer
Shroff, G. S., Strange, C. D., Altan, M., Carter, B. W., Ahuja, J., Godoy, M. C. B., Truong, M. T., & Vlahos, I. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.05.003 · Cited by 8
Caruso, M., Romeo, V., Stanzione, A., Buonerba, C., Lorenzo, G. D., & Maurea, S. (2021) · Applied Sciences · doi:10.3390/app11156930 · Cited by 5
Andrini, E., Lamberti, G., Mazzoni, F., Riccardi, F., Bonetti, A. V., Follador, A., Artioli, F., Genova, C., Barbieri, F., Frassoldati, A., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1027 · Cited by 7
Cesano, A., Cannarile, M. A., Gnjatic, S., Gomes, B., Guinney, J., Karanikas, V., Karkada, M., Kirkwood, J. M., Kotlán, B., Masucci, G. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001472 · Cited by 7
Bruno, D. S., Mitchell, C., Dowlati, A., Shamp, S., Fu, P., Rindeau, J., Zheng, Y., Machtay, M. X., & Biswas, T. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.06.007 · Cited by 6
Wang, W., Huang, W., Yang, X., Fang, C., Wei, H., Li, Z., Qiu, L., Zhong, R., Chen, C., Yuan, Q., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002939 · Cited by 6
Schneider, H., Illert, A.-L., Bamberg, F., & Eisenblätter, M. (2020) · Der Radiologe · doi:10.1007/s00117-020-00726-x · Cited by 6
Ou, F., Ahn, D. H., Dixon, J. G., Grothey, A. F., Lou, Y., Kasi, P. M., Hubbard, J. M., Cutsem, E. V., Saltz, L. B., Schmoll, H., et al. (2023) · Cancers · doi:10.3390/cancers15164117 · Cited by 6
Zhang, C., Chu, T., Wang, Q., Cheng, Y., Zhang, Y., Wang, R., Ma, L., Qian, C., Han, B., & Li, K. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0423 · Cited by 6
Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy.
Lee, G., Moon, S., Kim, J. H., Jeong, D. Y., Choi, J., Choi, J. Y., & Lee, H.-Y. (2024) · Investigative Radiology · doi:10.1097/rli.0000000000001096 · Cited by 6
Liu, B., Wu, L., Liu, C., Long, X., Hu, S., Zhang, L., Liu, Z., & Liang, C. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.33178 · Cited by 7
Ongoing evolution of response assessment in glioma: Where do we stand?
Yang, X., Li, Y., Ming, H., Yu, S., & Ren, B. (2018) · Glioma · doi:10.4103/glioma.glioma_13_18 · Cited by 6
Quantitative Imaging Assessment for Clinical Trials in Oncology
Hersberger, K. E., Mendiratta‐Lala, M., Fischer, R., Kaza, R. K., Francis, I. R., Olszewski, M. S., Harju, J. F., Shi, W., Manion, F. J., Al-Hawary, M. M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7331 · Cited by 6
Yin, K.-L., Li, M., Liao, R., Shi, Z., Qiu, J., Xiang, L., Duan, Y., Ye, W.-T., Wu, Z.-Y., Du, C., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-167 · Cited by 5
Checkpoint inhibitors in the treatment of cutaneous malignant melanoma.
Lutzky, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.13 · Cited by 6
Immune-modified response criteria — an iterative learning process?
Ott, P. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.36 · Cited by 6
Huang, C., Tang, X., Li, S., Wang, Q., Xie, B., Xu, J., & Lin, Y. (2019) · Journal of Cancer · doi:10.7150/jca.29672 · Cited by 6
Yılmaz, M. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220949642 · Cited by 6
2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer
Kang, X., Qin, J., Zhang, R., Wang, Z., Zheng, Q., Li, Y., Xu, J., Huang, J. L., Wang, X., Hui, Z., et al. (2021) · Annals of Esophagus · doi:10.21037/aoe-21-64 · Cited by 6
Zhang, Z., Xie, C., Gao, T., Yang, Y., Yang, Y., & Zhao, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-10613-y · Cited by 6
Simó, M., Vercher-Conejero, J. L., Viteri, S., & García‐Velloso, M. J. (2021) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2021.02.003 · Cited by 6
Jajodia, A., Goel, V., Patnaik, N., Pasricha, S., Gupta, G., Batra, U., & Talwar, V. (2022) · Tomography · doi:10.3390/tomography8030110 · Cited by 5
Chen, M. I.-C., Smith, D. A., Yoon, J. G., Vos, D. J., Kikano, E. G., Tirumani, S. H., & Ramaiya, N. H. (2022) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001315 · Cited by 5
Ayati, N., Araghi, Z. J., Hoellwerth, M., Schweighofer-Zwink, G., Hitzl, W., Koelblinger, P., Pirich, C., & Beheshti, M. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06247-8 · Cited by 5
Yirgin, İ. K., Doğan, İ., Engin, G., Vatansever, S., & Ertürk, Ş. M. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1898_22 · Cited by 5
Sahai, V., Griffith, K. A., Lin, B. S.-L., Soares, H. P., Chandana, S. R., Crysler, O., Kumar‐Sinha, C., Enzler, T., Dippman, D., Gunchick, V., et al. (2024) · Med · doi:10.1016/j.medj.2024.10.024 · Cited by 5
Fortpied, C., & Vinches, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00634 · Cited by 5
Castellanos, S. H., Pagano, A., Plodkowski, A. J., Girshman, J., Hellmann, M. D., Rizvi, H. A., Flynn, J. R., Zheng, J., Capanu, M., Halpenny, D. F., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.020 · Cited by 5
Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors
Mohammed, N., Zhou, R., & Xiong, Z. (2021) · British Journal of Radiology · doi:10.1259/bjr.20210228 · Cited by 5
Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy
Kim, E. Y., Kim, Y. S., Park, I., Ahn, H. K., Lee, H., & Kim, J. H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.129 · Cited by 5
Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapy
Weidhaas, J. B., McGreevy, K. M., Marco, N., Sundahl, N., Cabanski, C. R., Spencer, C. N., LaVallee, T. M., Ost, P., & Telesca, D. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06842-3 · Cited by 4
Igase, M., Hagimori, K., Inanaga, S., Mizoguchi, H., ITAMOTO, K., Sakurai, M., Motegi, T., Yamamoto, H., Kato, M., Shiga, T., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013623 · Cited by 4
Nishino, M., Hong, F., Ricciuti, B., Hatabu, H., & Awad, M. M. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00478 · Cited by 4
Wason, J. M. S., Dentamaro, A., & Eisen, T. G. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.002 · Cited by 4
Imaging of Novel Oncologic Treatments in Lung Cancer Part 1
Halpenny, D. F., O’Dwyer, E., Girshman, J., & Ginsberg, M. S. (2019) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000451 · Cited by 4
Gorospe, L., Pacios-Blanco, R. E., & Garrido, P. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2019.10.023 · Cited by 4
Pseudoprogression in lung cancer: a case report
Meoni, G., Decarli, N., Benucci, M., Raspanti, C., & Ribecco, A. S. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00022 · Cited by 4
Simó, M., Vercher-Conejero, J. L., Viteri, S., & García‐Velloso, M. J. (2021) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2021.02.001 · Cited by 4
Introduction on Nuclear Medicine and Immunology
Harsini, S., Alavi, A. A., & Rezaei, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_1 · Cited by 4
Li, X., Ma, Q., Chen, C., Li, H., & Cao, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958905 · Cited by 4
Prieto, L. P., & Miguel, L. S. S. (2013) · Journal of Veterinary Internal Medicine · Cited by 4
Cutting the Brakes: Immunotherapy With PD-1 Inhibitors
Sweis, R. F., & Luke, J. J. (2017) · Clinical skin cancer · doi:10.1016/j.clsc.2017.09.001 · Cited by 3
Medical oncology and pancreatic cancer: what the radiologist needs to know
Fogelman, D. R., & Varadhachary, G. A. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1432-9 · Cited by 3
Critères d’évaluation de la réponse tumorale aux inhibiteurs des points de contrôle immunitaire
Wasielewski, E., & Cortot, A. B. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.06.007 · Cited by 3
Provencio, M., Carcereny, E., & Artal, A. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02072-4 · Cited by 3
Efficacy Considerations in Phase I Trials
Alshammari, K., Taylor, K., & Siu, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-47682-3_10 · Cited by 1
Qin, Y., Zhang, H., Song, Y., Chen, C., Jin, C., & Shen, J. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03122-6 · Cited by 3
Assessing Radiological Response to Immunotherapy in Lung Cancer: An Evolving Arena
Rallis, K. S., Makker, S., Ghose, A., & Sideris, M. C. (2024) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10278 · Cited by 3
Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol
Marchal, C., Orillard, É., Calais, F., & Westeel, V. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014907.pub2 · Cited by 3
Pseudoprogression in patients on immunotherapy
Yudin, D. I., Лактионов, К. К., Саранцева, К. А., Breder, V. V., Реутова, Е. В., Borisova, O. I., & Сергеевич, А. М. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-10-10-14 · Cited by 3
Immunotherapy for Renal Cell Carcinoma
Qu, L., Wu, D., He, H., Xu, X., & Chen, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77377 · Cited by 3
Ferrara, R., Imbimbo, M., Paget‐Bailly, S., Malouf, R. S., Calais, F., Agazzi, G. M., Marchal, C., & Westeel, V. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257 · Cited by 3
Inhibiting tumor cell-intrinsic UBA6 by inosine augments tumor immunogenicity
He, B., Zhang, L., Jiang, L., Yu, L., Li, Q., Tian, X., He, J.-Q., Zeng, L., Yang, Y., Wang, C., et al. (2021) · doi:10.21203/rs.3.rs-620390/v1 · Cited by 82
Granata, V., Fusco, R., Pupo, D., Alfieri, A., Caranci, F., Riga, M. G., Feo, M. E. D., Sgariglia, L., Carrafiello, G., Karaboue, M. A., et al. (2025) · Infectious Agents and Cancer · doi:10.1186/s13027-025-00695-7 · Cited by 3
Response evaluation to systemic therapy in HCC: Current challenges and future perspectives
Matute‐González, M., Ronot, M., Chernyak, V., Sangro, B., & Rimola, J. (2025) · Hepatology · doi:10.1097/hep.0000000000001621 · Cited by 3
Macilwraith, P., Shackleton, M. J., Haydon, A. M., Nadebaum, D. P., Mar, V. J., Naranbhai, V., & Cherk, M. H. (2026) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.70066 · Cited by 2
Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol
Marchal, C., Orillard, É., Calais, F., & Westeel, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014907 · Cited by 2
Gebauer, B., Denecke, T., Savic, L. J., Hering, A. H., Schierle, K., Jentzsch, M., & Hacker, U. T. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_1-1 · Cited by 2
Wu, H., Weng, G. Z., Sun, L. N., Pan, Z. C., Zhang, L., Chen, Q., & Shi, C. M. (2023) · Cancer Management and Research · doi:10.2147/cmar.s415629 · Cited by 3
Heimer, M. M., Cimic, A., Kloiber-Langhorst, S., Antons, M. J., Stueckl, J., Hirner-Eppeneder, H., Kunz, W. G., Dietrich, O., Ricke, J., Herr, F. L., et al. (2025) · European Radiology Experimental · doi:10.1186/s41747-025-00597-8 · Cited by 2
Farnebo, J., Suzuki, T., Paris, R. V., Sandström, P., & Blomqvist, L. (2017) · European Journal of Radiology Open · doi:10.1016/j.ejro.2017.03.003 · Cited by 2
Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy
Weidhaas, J. B. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_9 · Cited by 2
How I Treat Non–Small Cell Lung Cancer Refractory to Immunotherapy
Wong, S. K., & Horn, L. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000482 · Cited by 2
Evaluation of cancer outcome assessment using MRI: A review of deep-learning methods
Mazaheri, Y., Thakur, S. B., Bitencourt, A. G. V., Gullo, R. L., Hötker, A. M., Bates, . D. B., & Akın, O. (2022) · BJR|Open · doi:10.1259/bjro.20210072 · Cited by 3
Nishino, M., Wang, X., Ricciuti, B., Tseng, S.-C., Park, H., Alessi, J. V., Vaz, V. R., Hatabu, H., Lin, X., Christiani, D. C., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09658-1 · Cited by 2
Cancer Immunotherapy and Medical Imaging Research Trends from 2003 to 2023: A Bibliometric Analysis
Tang, S., Fan, T., Wang, X., Yu, C., Zhang, C., & Zhou, Y. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s457367 · Cited by 1
Pseudo-hyperprogression of Malignant Pleural Mesothelioma Treated with Nivolumab
Yanai, M., Sakamoto, T., Nonaka, T., Nakada, T., Matsuoka, S., Moriyama, S., Yamamoto, N., Teruya, Y., Funaki, Y., Harada, T., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4807-24 · Cited by 1
Verschueren, M. V., Tassopoulou, V. P., Visscher, R., Schuurkamp, J., Peters, B. J. M., Koopman, M., van de Garde, E. M. W., Egberts, T. C. G., & Bloem, L. T. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100118 · Cited by 1
Kitajima, K., Matsuda, K., Minami, T., Nakamura, A., Kuribayashi, K., Funaki, S., Kijima, T., & Yamakado, K. (2025) · Oncology · doi:10.1159/000546339 · Cited by 1
iRECIST: A Case Based Users Guide for Radiologists
Waters, C., & Halpenny, D. F. (2025) · Canadian Association of Radiologists Journal · doi:10.1177/08465371251355866 · Cited by 1
Lu, X., Zhu, L., Tan, B., Liang, Z., Chen, K.-H., Huang, S., Li, L., & Zhu, X. (2025) · BMC Cancer · doi:10.1186/s12885-025-14888-1 · Cited by 1
Metadata
- Authors
- Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Authors' Affiliations: Departments of 1Radiology and 2Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital; and 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Corresponding author
- Nishino, Mizuki
- Venue
- Clinical Cancer Research
- Published
- 2013-07-15
- Volume
- 19
- Issue
- 14
- Pages
- 3936-3943
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3740724
- OpenAlex
- W2153778867
- Cited by
- 522
- References
- 21
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 27 · 2023: 53 · 2022: 51 · 2021: 56 · 2020: 76 · 2019: 57 · 2018: 49 · 2017: 39 · 2016: 36 · 2015: 23 · 2014: 13 · 2013: 2
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5k23ca157631-02)
- National Cancer Institute (K23-CA157631, 1K23CA157631)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- immune-related response criteria, tumor response assessment, immunotherapy, advanced melanoma, ipilimumab, interobserver variability, time to progression, best overall response, RECIST
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Models, Biological, Terminology as Topic, Models, Statistical, Treatment Outcome, Clinical Trials, Phase II as Topic, Disease-Free Survival, Statistics, Nonparametric, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
